Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
Abstract Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyt...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2025-01-01
|
| Series: | The Egyptian Journal of Internal Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43162-025-00406-z |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571320598003712 |
|---|---|
| author | Aysun Seker Nurdan Senturk Durmus |
| author_facet | Aysun Seker Nurdan Senturk Durmus |
| author_sort | Aysun Seker |
| collection | DOAJ |
| description | Abstract Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyte imbalances such as hypocalcemia and hypophosphatemia. Developing monitoring strategies for electrolyte abnormalities can be facilitated by the increased awareness of this interaction. We present the case of a 62-year-old female patient who developed severe, symptomatic hypocalcemia and hypophosphatemia despite having normal renal function. These abnormalities occurred concomitantly during treatment with denosumab for osteoporosis and ferric carboxymaltose for iron deficiency anemia. |
| format | Article |
| id | doaj-art-a4840135dc0e49218c784f8789d0cdf4 |
| institution | Kabale University |
| issn | 2090-9098 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | The Egyptian Journal of Internal Medicine |
| spelling | doaj-art-a4840135dc0e49218c784f8789d0cdf42025-02-02T12:43:17ZengSpringerOpenThe Egyptian Journal of Internal Medicine2090-90982025-01-013711410.1186/s43162-025-00406-zDanger of co-administration ferric carboxymaltose and denosumab: hypophosphatemiaAysun Seker0Nurdan Senturk Durmus1Kartal Dr. Lütfi Kırdar City HospitalMarmara Üniversitesi Eğitim ve Araştırma HastanesiAbstract Both denosumab-induced hypocalcemia and ferric carboxymaltose infusion-related hypophosphatemia have been extensively documented. There are significant risks associated with combining ferric carboxymaltose parenteral infusions and denosumab, including potentially life-threatening electrolyte imbalances such as hypocalcemia and hypophosphatemia. Developing monitoring strategies for electrolyte abnormalities can be facilitated by the increased awareness of this interaction. We present the case of a 62-year-old female patient who developed severe, symptomatic hypocalcemia and hypophosphatemia despite having normal renal function. These abnormalities occurred concomitantly during treatment with denosumab for osteoporosis and ferric carboxymaltose for iron deficiency anemia.https://doi.org/10.1186/s43162-025-00406-zDenosumabFerric carboxymaltoseHypocalcemiaHypophosphatemia |
| spellingShingle | Aysun Seker Nurdan Senturk Durmus Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia The Egyptian Journal of Internal Medicine Denosumab Ferric carboxymaltose Hypocalcemia Hypophosphatemia |
| title | Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia |
| title_full | Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia |
| title_fullStr | Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia |
| title_full_unstemmed | Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia |
| title_short | Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia |
| title_sort | danger of co administration ferric carboxymaltose and denosumab hypophosphatemia |
| topic | Denosumab Ferric carboxymaltose Hypocalcemia Hypophosphatemia |
| url | https://doi.org/10.1186/s43162-025-00406-z |
| work_keys_str_mv | AT aysunseker dangerofcoadministrationferriccarboxymaltoseanddenosumabhypophosphatemia AT nurdansenturkdurmus dangerofcoadministrationferriccarboxymaltoseanddenosumabhypophosphatemia |